Testosterone Replacement Therapy, Explained Without the Confusion
Testosterone replacement therapy — TRT — has moved from the margins of men’s health into mainstream clinical conversation, and for good reason. Low testosterone affects millions of men, yet many still receive little more than a dismissive “your levels are a bit low, but that’s normal aging.” That answer doesn’t serve patients well, and it doesn’t reflect what the evidence says.
This guide is written for anyone trying to understand what TRT actually is, whether they might be a candidate, and what a responsible, physician-led approach looks like. It’s not a sales pitch. It’s the same conversation I’d have with a patient sitting across from me in the clinic.
Here’s what you need to know: TRT is a legitimate, guideline-supported treatment for a diagnosable medical condition. It is not a shortcut, not a lifestyle supplement, and not appropriate for every man experiencing fatigue or low libido. Candidacy requires both symptoms and objective laboratory findings — and management requires ongoing physician oversight. When it’s the right fit, the impact on quality of life can be substantial. When it’s not, the right physician will tell you that, too.
What follows is a plain-English walkthrough of the science, the clinical criteria, the delivery options, and what the research actually shows — so you can have an informed conversation with your care team.
Key Takeaways
- TRT is a physician-prescribed treatment for hypogonadism — clinically low testosterone confirmed by both symptoms and blood work.
- Symptoms alone are not sufficient for diagnosis; laboratory testing is required.
- The Endocrine Society and the American Urological Association both publish evidence-based guidelines governing appropriate TRT use.
- Multiple delivery formats exist — injections, topical gels, and pellets — each with distinct pharmacokinetic profiles.
- TRT is not appropriate for men who are actively trying to conceive without additional clinical management.
- Individual responses vary; outcomes depend on baseline health, adherence, and ongoing monitoring.
- A responsible TRT program includes regular lab monitoring and physician-led dose adjustments.
Table of Contents
- What Is Testosterone Replacement Therapy?
- The Biology Behind Low Testosterone
- Symptoms That Suggest TRT May Help
- Who Is a Candidate for TRT?
- How TRT Is Delivered
- What the Research Shows
- Myths vs. Facts
- LiteWell’s Clinical Approach
- Frequently Asked Questions
- Related LiteWell Services
- Related Insights
- References
- Medical Disclaimer
- Medication & Regulatory Disclosure
What Is Testosterone Replacement Therapy?
Testosterone replacement therapy is a medical treatment that restores testosterone to physiologically normal levels in men whose bodies are no longer producing adequate amounts on their own. It is prescribed for a condition called hypogonadism — sometimes referred to as testosterone deficiency syndrome — a diagnosable endocrine disorder recognized by the Endocrine Society, the American Urological Association (AUA), and the American Association of Clinical Endocrinology (AACE).
TRT does not add testosterone beyond what the body should naturally produce. The goal is restoration, not supraphysiologic elevation. That distinction matters clinically, ethically, and in terms of how treatment is monitored and adjusted over time.
The testosterone used in TRT is bioidentical — structurally identical to what the testes produce — and is delivered through a variety of FDA-approved formulations including injectable esters, topical gels, transdermal patches, buccal systems, nasal gels, and subcutaneous pellets. Each has a different pharmacokinetic profile, meaning the way testosterone enters, peaks, and clears the bloodstream varies by delivery method.
TRT is distinct from the anabolic steroids used in performance-enhancement contexts. Those products are typically synthetic derivatives used in supraphysiologic doses for purposes outside the scope of medical treatment. The confusion between the two is common — and damaging to patients who might benefit from legitimate TRT but avoid it due to stigma.
The Biology Behind Low Testosterone
To understand why testosterone levels fall, it helps to understand how production is regulated in the first place.
Testosterone synthesis is governed by the hypothalamic-pituitary-gonadal (HPG) axis — a feedback loop involving three organs:
- Hypothalamus: Releases gonadotropin-releasing hormone (GnRH) in pulsatile bursts.
- Pituitary gland: Responds to GnRH by secreting luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
- Testes: Respond to LH by producing testosterone; respond to FSH by supporting sperm production.
Testosterone then feeds back to the hypothalamus and pituitary, signaling them to reduce GnRH and LH release when levels are sufficient. This self-regulating loop keeps testosterone in a healthy range throughout early adulthood.
Starting in a man’s mid-30s, this system begins a gradual decline. Testosterone levels fall roughly 1–2% per year on average, though the rate varies considerably by individual. That decline is normal. But when the cumulative effect crosses a clinical threshold — and when it produces meaningful symptoms — it becomes a treatable condition rather than an expected inconvenience.
There are two primary types of hypogonadism:
- Primary hypogonadism: The testes themselves are not producing adequate testosterone despite normal pituitary signaling. LH and FSH are elevated because the pituitary is trying to compensate.
- Secondary hypogonadism: The pituitary or hypothalamus is not sending adequate signals to the testes. LH and FSH are low or inappropriately normal despite low testosterone. This is the more common pattern in aging men and those with obesity, sleep apnea, or chronic illness.
Identifying which type is present changes the treatment approach. Secondary hypogonadism in some men may be addressed with medications that stimulate endogenous production rather than replacing testosterone directly — a nuance that a thorough physician evaluation captures.
Beyond the HPG axis, several factors are known to suppress testosterone production or increase its conversion to estrogen:
- Elevated body fat (adipose tissue converts testosterone to estradiol via aromatase)
- Obstructive sleep apnea
- Chronic psychological stress and elevated cortisol
- Alcohol use and certain medications
- Autoimmune conditions and chronic inflammation
- Prior chemotherapy or radiation
Symptoms That Suggest TRT May Help
Testosterone influences a remarkably wide range of physiological functions. When levels fall below an individual’s optimal range, symptoms may appear across multiple domains. No single symptom is diagnostic — and many overlap with other conditions — but a cluster of symptoms in the right clinical context warrants investigation.
Physical Symptoms
- Persistent fatigue not explained by sleep or activity level
- Decreased muscle mass and difficulty building or maintaining strength
- Increased body fat, particularly visceral (abdominal) fat
- Reduced bone density (identified on DEXA scan in some patients)
- Loss of body hair, particularly in the legs and axillae
- Hot flashes or night sweats (less commonly reported, but documented)
- Gynecomastia — breast tissue development — in some cases
Cognitive Symptoms
- Difficulty concentrating or sustaining mental focus
- Brain fog — a subjective sense of mental sluggishness or cloudiness
- Reduced verbal fluency or word-finding difficulty
- Impaired working memory
Emotional and Psychological Symptoms
- Persistent low mood, anhedonia, or irritability
- Reduced motivation and drive
- Increased anxiety or emotional reactivity
- Reduced sense of well-being that doesn’t resolve with lifestyle adjustment
Sexual Symptoms
- Reduced libido — decreased interest in sexual activity
- Erectile dysfunction, particularly a loss of spontaneous or morning erections
- Reduced ejaculatory volume
- Decreased genital sensitivity
- Reduced fertility (TRT suppresses sperm production — see candidacy section)
Several validated questionnaires — including the Androgen Deficiency in the Aging Male (ADAM) questionnaire and the Aging Males’ Symptoms (AMS) scale — can help quantify symptom burden. These tools don’t make a diagnosis, but they provide a useful clinical baseline before and during treatment.
Who Is a Candidate for TRT?
This is the question that separates responsible TRT practice from irresponsible prescribing. According to current Endocrine Society guidelines, TRT is appropriate when a patient has both of the following:
- Unequivocal symptoms of androgen deficiency — a meaningful, functionally impactful constellation of the symptoms described above.
- Consistently low serum testosterone confirmed by at least two morning blood draws — because testosterone levels fluctuate diurnally (they’re highest in the morning) and vary by lab, single measurements are considered insufficient for diagnosis.
The Endocrine Society defines low testosterone as a total testosterone below 300 ng/dL in most laboratory standards, though some patients with low-normal total levels may have clinically meaningful deficiency when free testosterone (the biologically active fraction) is also evaluated. The interpretation depends on the laboratory reference range, the patient’s symptom burden, and clinical context.
TRT is generally not recommended for men who:
- Are actively trying to conceive naturally (TRT suppresses LH, FSH, and sperm production)
- Have active or suspected prostate cancer
- Have a hematocrit above 54% (polycythemia vera or secondary erythrocytosis)
- Have severe untreated obstructive sleep apnea
- Have had a myocardial infarction or stroke within the past 6 months (clinical judgment applies)
- Have a palpable breast mass or active breast cancer
- Have uncontrolled congestive heart failure
Before initiating TRT, a complete evaluation typically includes: total and free testosterone, LH, FSH, complete blood count, comprehensive metabolic panel, PSA (in men over 40), and a review of current medications and health history. Additional testing — SHBG, prolactin, thyroid function, estradiol — may be ordered based on the clinical picture.
Men who want to preserve fertility while addressing testosterone deficiency have other options — clomiphene citrate, human chorionic gonadotropin (hCG), and anastrozole are sometimes used in fertility-preservation protocols — though these carry their own clinical considerations and are not right for every patient.
How TRT Is Delivered
Several FDA-approved delivery methods exist, each with distinct advantages, limitations, and monitoring requirements. The right choice depends on patient preference, lifestyle, lab response, and clinical factors.
Intramuscular and Subcutaneous Injections
Testosterone cypionate and testosterone enanthate — both injectable ester formulations — are among the most commonly prescribed forms. Injections are typically administered every 1–2 weeks intramuscularly (IM) or more frequently subcutaneously (SQ) in smaller doses to reduce fluctuation. Self-administration at home is common after proper instruction.
Advantages: Cost-effective, highly customizable dosing, reliable absorption. Limitations: Levels peak sharply after injection and trough before the next dose, which some patients experience as mood or energy fluctuation. More frequent, lower-dose injections mitigate this significantly.
Topical Gels and Creams
Topical testosterone gels (applied to the shoulder, upper arm, or inner thigh) and compounded creams deliver testosterone transdermally. Daily application produces more stable serum levels than infrequent injections.
Advantages: Ease of use, smooth level curve, no needles. Limitations: Transfer risk to partners or children through skin contact (requiring care around application sites and hand-washing), variable absorption between individuals.
Subcutaneous Pellets
Testosterone pellets are implanted beneath the skin — typically in the upper buttock — in a brief in-office procedure. They dissolve slowly over 3–6 months, delivering a steady release without daily administration.
Advantages: Excellent level consistency, no daily adherence burden. Limitations: Once placed, dosage cannot be adjusted until the next insertion cycle. Minor procedural risks (infection, extrusion) apply. Pellets are not interchangeable across all patients and require careful dosing at placement.
Other Formulations
Testosterone undecanoate (Aveed) is a long-acting injectable approved for in-office administration every 10 weeks. Testosterone nasal gel (Natesto) is a three-times-daily intranasal option with a shorter half-life and lower suppression of sperm production — a consideration for men who wish to preserve fertility while on TRT.
What the Research Shows
The evidence base for TRT has grown substantially over the past two decades, and guideline bodies have sharpened their positions accordingly.
Endocrine Society Clinical Practice Guidelines — the most widely referenced framework in endocrinology — support TRT for men with confirmed symptomatic hypogonadism. The Society recommends testosterone therapy to improve sexual function, mood, bone density, and lean body mass in appropriately selected patients, while emphasizing that treatment goals and monitoring protocols must be individualized.
The American Urological Association (AUA) published its own guidelines on testosterone deficiency, affirming that hypogonadism is a medical condition that may be treated with TRT when properly diagnosed, while highlighting the importance of cardiovascular risk evaluation and prostate monitoring.
The TRAVERSE Trial — a large cardiovascular safety trial funded by the NIH and completed in 2023 — addressed longstanding questions about whether TRT increases heart attack or stroke risk. The trial found that testosterone replacement in middle-aged and older men with hypogonadism and cardiovascular risk factors did not result in a significantly higher rate of major adverse cardiovascular events compared to placebo. The trial also noted a higher incidence of certain outcomes including atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group, underscoring the continued importance of individual risk assessment and physician oversight.
Earlier concerns about cardiovascular risk — stemming largely from observational studies with significant methodological limitations — led to years of over-caution in clinical practice. Current evidence supports a more nuanced, patient-specific assessment rather than a blanket contraindication for cardiovascular history.
Research on prostate cancer risk and TRT has also evolved. Current evidence does not support the hypothesis that TRT causes prostate cancer in men with no prior diagnosis. The Endocrine Society’s guidelines acknowledge this shift, though PSA monitoring during treatment remains standard practice and men with active or suspected prostate cancer remain contraindicated for TRT.
On symptom outcomes, randomized controlled trial data — including from the Testosterone Trials (TTrials) — show improvements in sexual function, mood, bone density, and walking distance in appropriately selected older men with low testosterone. Individual responses vary considerably, and not all patients achieve equivalent benefit.
Myths vs. Facts
Myth: TRT causes prostate cancer.
Fact: Current evidence does not support a causal relationship between TRT and prostate cancer in men without a prior diagnosis. Active prostate cancer remains a contraindication, and PSA monitoring during treatment is standard.
Myth: TRT is the same as steroid use.
Fact: TRT uses bioidentical testosterone at physiologic doses to restore normal levels. Anabolic steroid use involves synthetic derivatives at supraphysiologic doses for performance enhancement — a fundamentally different context.
Myth: Any man with fatigue or low libido should start TRT.
Fact: Symptoms alone are not sufficient for diagnosis. TRT requires confirmed laboratory evidence of low testosterone alongside meaningful symptoms. Many causes of fatigue and low libido are unrelated to testosterone and won’t respond to TRT.
Myth: Once you start TRT, you’re on it forever.
Fact: TRT can be discontinued. Endogenous production may take time to resume — particularly after longer treatment durations — and post-TRT management strategies exist for men who wish to stop. Some men use TRT for a defined period and transition off with physician guidance.
Myth: TRT is safe without monitoring.
Fact: TRT requires ongoing lab monitoring — at minimum, testosterone levels, hematocrit, and PSA. Unsupervised use creates real risks including polycythemia, cardiovascular strain, and undetected PSA elevation.
Myth: Low testosterone is just a normal part of aging — nothing to be done.
Fact: While some testosterone decline with age is expected, clinically significant hypogonadism that impairs quality of life is a diagnosable and treatable medical condition. Age alone is not a reason to withhold evaluation.
LiteWell’s Clinical Approach
LiteWell is a physician-led men’s health clinic grounded in the principle that patients deserve more than a rushed referral or a dismissive lab interpretation. Every TRT evaluation begins with a thorough clinical conversation — not a checkbox form.
Our process starts with a Free Medical Fit Call: a no-obligation conversation to determine whether LiteWell’s approach is aligned with what a patient is looking for. This isn’t a sales call — it’s a chance to ask questions, understand the process, and make sure expectations are realistic on both sides.
Patients who move forward complete a Premier Discovery Intake — a comprehensive evaluation that includes a detailed health history, symptom review using validated instruments, and a laboratory panel designed to give a complete picture of hormonal, metabolic, and cardiovascular health. We don’t diagnose from a single testosterone number. We diagnose from the full picture.
Treatment plans, when indicated, are personalized. Delivery method, dose, and monitoring schedule are chosen based on individual factors — not a one-size protocol. LiteWell operates on a hybrid care model: patients have access to both in-person consultation at our Edina clinic and telehealth visits for follow-up and monitoring, making ongoing physician oversight as convenient as it needs to be.
What we won’t do: prescribe TRT to men who don’t meet clinical criteria, deprioritize monitoring to reduce friction, or overpromise outcomes. The goal is optimal health — not a number on a lab report.
Frequently Asked Questions
What is the difference between TRT and testosterone boosters sold at supplement stores?
Over-the-counter “testosterone boosters” are typically dietary supplements — zinc, vitamin D, ashwagandha, and similar compounds — that may support general hormonal health but do not contain testosterone and are not regulated as drugs. They are not equivalent to TRT and are not an appropriate treatment for diagnosed hypogonadism. TRT involves actual testosterone, requires a prescription, and is regulated by the FDA.
How do I know if my testosterone is actually low?
Low testosterone is confirmed through blood work — specifically, two separate morning serum testosterone measurements taken on different days. A single low result is not sufficient for diagnosis because testosterone levels fluctuate throughout the day and can vary due to illness, stress, or recent activity. Symptoms must also be present and meaningful to meet diagnostic criteria.
What testosterone level is considered low?
Most laboratory reference ranges use 300 ng/dL as the lower threshold for total testosterone. However, this number is a guideline, not an absolute cutoff. Some men with levels in the 300–400 ng/dL range may have clinically significant symptoms when free testosterone — the biologically active fraction — is also low. The clinical picture always takes precedence over a single number.
Will TRT affect my fertility?
Yes, and this is one of the most important considerations for men of reproductive age. TRT suppresses the pituitary signals that stimulate sperm production. Most men on TRT experience a significant reduction in sperm count, and some become temporarily infertile during treatment. Men who are actively trying to conceive should discuss fertility-preserving alternatives with their physician before starting TRT.
How long does it take to feel results from TRT?
Individual responses vary, and timelines differ by symptom domain. Some patients report improvements in mood and energy within 3–6 weeks. Sexual function changes may take 3–6 months. Body composition shifts — increased lean mass, reduced fat — typically require several months of consistent treatment alongside appropriate nutrition and exercise. TRT is not a rapid fix, and outcomes depend on multiple factors including baseline health, lifestyle, and adherence.
Is TRT safe for men with heart disease?
This question has evolved significantly with the publication of the TRAVERSE trial in 2023, which found that TRT in men with hypogonadism and cardiovascular risk factors did not significantly increase the rate of major adverse cardiac events compared to placebo. However, the trial did identify elevated rates of certain events including atrial fibrillation and pulmonary embolism. Men with active cardiovascular conditions require individualized physician assessment before initiating TRT. A physician-led evaluation of cardiovascular risk is essential, not optional.
Does TRT cause prostate cancer?
Current evidence does not support a causal link between TRT and the development of prostate cancer in men without a prior diagnosis. This question was a major concern in earlier decades based on the “androgen fuel” hypothesis, but that hypothesis has been substantially revised in light of more recent data. Active prostate cancer remains a contraindication, and routine PSA monitoring during TRT is standard practice.
Can TRT help with depression or anxiety?
Some patients with hypogonadism and mood symptoms report improvement in depressive symptoms and emotional well-being after TRT. The Testosterone Trials included a mood sub-study that showed modest improvements in self-reported mood and depressive symptoms in older men with low testosterone. TRT is not a treatment for primary depression or anxiety disorders, and men with significant mental health symptoms should also be evaluated and managed by appropriate mental health providers.
What monitoring is required while on TRT?
Responsible TRT management includes regular laboratory monitoring — typically at 3 months after initiation, then every 6–12 months once levels are stable. Standard labs include total and free testosterone (to confirm therapeutic range), hematocrit (to screen for polycythemia), PSA (prostate monitoring), and a metabolic panel. Additional monitoring may be ordered based on individual risk factors. Unsupervised TRT without laboratory follow-up carries meaningful risks.
What happens if I stop TRT?
Endogenous testosterone production is suppressed during TRT because external testosterone signals the pituitary to reduce LH and FSH output. When TRT is stopped, it typically takes weeks to months for natural production to resume. In men who have been on TRT for extended periods, this recovery may be slower and incomplete. Post-TRT management strategies — including medications to stimulate the HPG axis — are sometimes used under physician guidance for men transitioning off treatment.
Can younger men be candidates for TRT?
Yes. While hypogonadism is more prevalent with advancing age, it can affect men of any age. Younger men may develop hypogonadism due to pituitary disorders, testicular conditions, prior illness, medication effects, or other causes. The diagnostic criteria are the same regardless of age: confirmed low testosterone plus meaningful symptoms. Younger men with a desire to preserve fertility require additional consideration around treatment approach.
How is TRT different from HRT for women?
Both involve restoring hormones that the body no longer produces in adequate amounts, and both are guided by similar principles — symptom relief, quality-of-life improvement, and evidence-based management. The specific hormones, delivery methods, monitoring parameters, and risk considerations differ. TRT in men involves testosterone; HRT in women typically involves estrogen, progesterone, or both. Physicians managing either form of hormone therapy should be familiar with the specific guidelines governing each.
Related LiteWell Services
- Hormone Optimization Program — Comprehensive hormonal evaluation and physician-led treatment for testosterone deficiency and related conditions.
- Premier Discovery Intake — A thorough baseline assessment covering metabolic health, hormonal status, cardiovascular risk, and lifestyle factors.
- Metabolic Health & Weight Management — Addressing body composition, insulin resistance, and metabolic factors that contribute to hormonal decline.
- Sleep Health Optimization — Sleep apnea and sleep quality assessment, given the established relationship between sleep disruption and testosterone suppression.
- Free Medical Fit Call — A no-obligation consultation to determine whether LiteWell is the right fit before committing to an intake appointment.
Related Insights
- Low Testosterone vs. Normal Aging: How to Tell the Difference
- TRT and Fertility: What Men Need to Know Before Starting
- Understanding Your Testosterone Lab Results: A Plain-English Guide
- Sleep, Stress, and Testosterone: How Lifestyle Factors Affect Hormone Health
- The First 90 Days on TRT: What to Expect and How to Track Progress
References
- Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018. Published by the Endocrine Society. Available at: endocrine.org
- Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology. 2018. Published by the American Urological Association. Available at: auanet.org
- Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial). New England Journal of Medicine. 2023. Available at: nejm.org
- Snyder PJ, et al. Effects of Testosterone Treatment in Older Men (Testosterone Trials). New England Journal of Medicine. 2016. Available at: nejm.org
- Khera M, et al. Adult-Onset Hypogonadism. Mayo Clinic Proceedings. 2016. Available at: mayoclinicproceedings.org
- American Association of Clinical Endocrinology. Clinical Practice Guidelines for the Evaluation and Treatment of Hypogonadism in Adult Male Patients. Available at: aace.com
- National Institutes of Health, National Institute on Aging. Testosterone and Aging: Clinical Research Directions. Available at: nih.gov
Medical Disclaimer
This article is written for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Individual health circumstances vary, and the information presented here may not apply to every reader. Always consult a qualified physician or licensed healthcare provider before making any decision about your health, medications, or treatment plan. LiteWell physicians are available to evaluate your specific situation during a clinical consultation.
Medication & Regulatory Disclosure
Testosterone replacement therapy involves prescription medications regulated by the U.S. Food and Drug Administration (FDA). Testosterone is a Schedule III controlled substance under the Controlled Substances Act. TRT may only be legally prescribed by a licensed medical provider following a clinical evaluation that meets diagnostic criteria. LiteWell does not prescribe controlled substances without a thorough medical evaluation, and all prescriptions are issued in compliance with applicable state and federal regulations. Outcomes described in this article reflect published research and individual patient reports; results vary and are not guaranteed.
